LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LBRX LB Pharmaceuticals Inc

休市中 05-22 16:00:00 EDT

28.12

+0.12

+0.43%

盘后28.12

+0.000.00%

16:04 EDT

最高29.71	最低27.93	成交量14.54万
今开28.50	昨收28.00	日振幅6.36%
总市值8.04亿	流通市值5.34亿	总股本2,861万
成交额410.34万	换手率0.77%	流通股本1,900万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals Inc","latestPrice":28.12,"timestamp":1779480000000,"preClose":28,"halted":0,"volume":145378,"hourTrading":{"tag":"盘后","latestPrice":28.12,"preClose":28.12,"latestTime":"16:04 EDT","volume":1377,"amount":38726.94,"timestamp":1779480289434,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0042857142857143215,"floatShares":19000000,"shares":28605700,"eps":-1.358,"marketStatus":"休市中","change":0.12,"latestTime":"05-22 16:00:00 EDT","open":28.5,"high":29.71,"low":27.93,"amount":4103417,"amplitude":0.063571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.358,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":28,"preHourTrading":{"tag":"盘前","latestPrice":29.02,"preClose":28,"latestTime":"09:28 EDT","volume":44,"amount":1267.480016,"timestamp":1779456480004,"change":1.02,"changeRate":0.036429,"amplitude":0.016786},"postHourTrading":{"tag":"盘后","latestPrice":28.12,"preClose":28.12,"latestTime":"16:04 EDT","volume":1377,"amount":38726.94,"timestamp":1779480289434,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7348120080753575},"requestUrl":"/m/hq/s/LBRX","defaultTab":"news","newsList":[{"id":"1118992301","title":"LB Pharmaceuticals公布LB-102治疗精神分裂症二期NOVA-1试验结果获《JAMA Psychiatry》刊载","url":"https://stock-news.laohu8.com/highlight/detail?id=1118992301","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118992301?lang=zh_cn&edition=full","pubTime":"2026-04-23 04:06","pubTimestamp":1776888376,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals公司宣布，其针对精神分裂症治疗的创新药物LB-102二期临床试验NOVA-1的研究成果，已正式发表于国际权威期刊《美国医学会精神病学杂志》（JAMA Psychiatry）。该论文的刊登标志着该药物临床数据获得学界认可，为后续研发提供重要学术支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166137553","title":"LB Pharmaceuticals启动Lb-102针对精神分裂症患者的关键性III期临床试验（Nova-2）","url":"https://stock-news.laohu8.com/highlight/detail?id=1166137553","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166137553?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:05","pubTimestamp":1774440300,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc (LBRX) 已正式启动其候选药物Lb-102针对精神分裂症患者的一项关键性III期临床试验，该试验代号为Nova-2。此举标志着该药物的研发进程迈入了至关重要的新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124088225","title":"LB制药宣布完成1亿美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1124088225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124088225?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:11","pubTimestamp":1770297074,"startTime":"0","endTime":"0","summary":"纽约，2026年2月5日——专注于开发精神分裂症、双相抑郁等神经精神疾病创新疗法的后期生物制药公司LB Pharmaceuticals Inc今日宣布，已与特定机构投资者签署证券购买协议，通过私募方式发行3,306,571股普通股及可认购最多1,417,107股普通股的预融资权证。普通股发行价为每股21.17美元，预融资权证发行价为每股21.1699美元。在扣除交易费用前，本次私募预计可为公司筹集约1亿美元总收益，交易预计于2026年2月6日左右完成，最终需满足惯例交割条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","LBRX","LB","BK4007","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167670995","title":"LB Pharmaceuticals启动双相抑郁症II期Illuminate-1试验 拓展LB-102研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1167670995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167670995?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:02","pubTimestamp":1769432543,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals近日正式启动针对双相抑郁症的II期临床试验Illuminate-1，标志着其核心候选药物LB-102的研发版图实现重要拓展。该试验旨在评估LB-102在双相抑郁患者中的疗效与安全性，为这一难治性精神疾病提供潜在创新疗法。\nIlluminate-1试验的推进不仅深化了LB-102的临床开发路径，更彰显了公司对精神神经疾病治疗领域的战略聚焦。通过阶段性临床试验数据的积累，LB Pharmaceuticals有望进一步验证该药物的治疗潜力，为后续研发决策提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604391875","title":"Lb Pharmaceuticals Inc盘中异动 早盘急速下挫5.22%报20.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604391875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604391875?lang=zh_cn&edition=full","pubTime":"2026-01-17 00:17","pubTimestamp":1768580279,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日00时17分，Lb Pharmaceuticals Inc股票出现异动，股价大幅跳水5.22%。截至发稿，该股报20.27美元/股，成交量4.6651万股，换手率0.18%，振幅6.20%。Lb Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.12%。Lb Pharmaceuticals Inc公司简介：LB Pharmaceuticals Inc 是一家临床阶段生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260117001759953d1c42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104130764","title":"LB制药强化领导团队，企业事务及人力与文化部门迎来关键任命","url":"https://stock-news.laohu8.com/highlight/detail?id=1104130764","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104130764?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:01","pubTimestamp":1767700876,"startTime":"0","endTime":"0","summary":"LB制药近日宣布对其领导团队进行重要人事调整，在企业事务及人力与文化部门任命了关键高管，以进一步巩固公司的管理架构。\n此次任命旨在加强公司内部治理与人才发展战略，通过引入资深管理人才提升组织效能。新任命的高管将负责推动企业文化建设、人才发展体系优化以及内外部沟通策略的完善。\n公司表示，这一系列人事变动将有助于提升企业运营效率，为未来的业务拓展奠定坚实基础。通过强化领导团队，LB制药展现出对组织发展与人才战略的高度重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159324610","title":"新闻稿：LB Pharmaceuticals根据纳斯达克上市规则5635(c)(4)向新员工授予诱因奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1159324610","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159324610?lang=zh_cn&edition=full","pubTime":"2025-12-11 06:09","pubTimestamp":1765404561,"startTime":"0","endTime":"0","summary":"纽约，2025年12月10日—— LB Pharmaceuticals Inc今天宣布，公司已向新的首席商业官Kaya Pai Panandiker授予一项股权奖励，该奖励超出但需遵循LB Pharmaceuticals Inc 2025年股权激励计划的条款与条件。该股权奖励于2025年12月10日授予，依据纳斯达克上市规则5635中提供的“诱因授予”例外，旨在作为Pai Panandiker女士进入LB Pharmaceuticals工作的诱因。Pai Panandiker女士获得了以21.36美元的行使价格购买195,000股LB Pharmaceuticals普通股的期权，行使价格为授予日LB Pharmaceuticals普通股的收盘价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LBRX","BK4233","LB","NQmain","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lbpharma.us","stockEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.1152},{"period":"3month","weight":0.1865},{"period":"6month","weight":0.8343},{"period":"1year","weight":0.8747},{"period":"ytd","weight":0.2633}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LB Pharmaceuticals Inc于2015年9月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新疗法。","exchange":"NASDAQ","name":"LB Pharmaceuticals Inc","nameEN":"LB Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"LB Pharmaceuticals Inc,LBRX,LB Pharmaceuticals Inc股票,LB Pharmaceuticals Inc股票老虎,LB Pharmaceuticals Inc股票老虎国际,LB Pharmaceuticals Inc行情,LB Pharmaceuticals Inc股票行情,LB Pharmaceuticals Inc股价,LB Pharmaceuticals Inc股市,LB Pharmaceuticals Inc股票价格,LB Pharmaceuticals Inc股票交易,LB Pharmaceuticals Inc股票购买,LB Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LB Pharmaceuticals Inc(LBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供LB Pharmaceuticals Inc(LBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}